Samsung Bioepis gets OK to sell Flixabi in Europe

Samsung Bioepis got a green light from the European Commission to sell its biosimilar drug Flixabi in Europe, the company said on Monday. Flixabi is a biosimiliar product of Janssen’s Remicade.

Samsung already obtained a sales license in Korea for the same product called Renflexis, which treats rheumatis arthritis, ulcerative colitis, Crohn’s disease, spondylarthritis ankylopoietica and psoriatic arthritis. The drug had a market worth about 9 trillion won globally as of 2014.

The new drug will be sold in 31 European countries, including 28 EU member nations and three European Economic Community members - Norway, Iceland and Liechtenstein - with a price tag about 30 to 40 percent lower than Remicade.

Samsung Bioepis already sells another biosimilar product called Bennepali, which refers to the autoimmune disorder treatment drug
Enbrel.